ArticleWorld journal of urology2025
A comparative analysis of the outcomes of Rezūm therapy based on prostate size: a four-year retrospective analysis.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07169773 (Comparison Between Convective Radiofrequency Water Vapor Thermal Ablation), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison Between Convective Radiofrequency Water Vapor Thermal Ablation (REZUM) Versus Tamsulosin in Management of Lower Urinary Tract Symptoms in Patients With Benign Prostatic Enlargement
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- How does PSA change after water vapor therapy? A systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- A Comprehensive Review of Minimally Invasive Surgical Therapies for Voiding Dysfunction in Benign Prostatic Hyperplasia: Past Failures, Contemporary Successes and Future Innovations.Current urology reports · 2026Review
- Real-World Long-Term Outcomes of Rezūm Therapy for Large-Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study.Lower urinary tract symptoms · 2026Article
- Predictors of surgical retreatment following Rezūm water vapor therapy: a multi-center real-world cohort study.World journal of urology · 2026Observational
- Association between volume per injection and treatment failure after water vapor thermal therapy.BMC urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the safety and efficacy of Rezūm therapy in small versus large prostates through a four-year follow-up. PATIENTS AND
methodsOne-hundred seventy patients who underwent Rezūm therapy were retrospectively included and divided into 2 equal groups, small (˂ 80gm) and large prostate groups (80-120 gm). Both groups were assessed preoperatively and at 3, 12, 24, 36, and 48 months post-procedure for operative time, number of vapor injection, catheterization time, hospital stay and post-procedure: prostatic size, prostate-specific antigen (PSA), post-void residual (PVR), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF) and complications.
resultsThe number of vapor injections was significantly higher in the large prostate group compared to the small prostate group (p < 0.001). Operative time and catheter duration were significantly longer in the large prostate group (p < 0.001), while hospital stay was similar between groups (p = 0.407). At 48 months post-Rezūm, both groups demonstrated statistically significant improvement in all measured outcomes (Qmax, IPSS, PVR, QoL, PSA, IIEF, and prostate size) (p < 0.05). Regarding postoperative complications, there were no significant differences between the groups except that the need for retreatment was significantly higher in the large prostate group.
conclusionRezūm therapy offers a safe and effective treatment option for both small and large prostates with sustained improvement over four years. However, patients with large prostates exhibited a higher retreatment rate (15.2%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.